









Markets
/
Stocks
/
nasdaq-gtbp
/

GT Biopharma Inc

GTBP

0.618USD

-0.005-0.82%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

2.02MMarket Cap

LossP/E TTM



GT Biopharma Inc

0.618

-0.005-0.82%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of GT Biopharma Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

GT Biopharma Inc's Score

Industry at a Glance

Industry Ranking

176 / 407

Overall Ranking

303 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

11.000

Target Price

+1665.37%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

GT Biopharma Inc Highlights

StrengthsRisks

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. Its TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer (NK) cells. The Company is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease such as for the treatment of patients infected by the human immunodeficiency virus (HIV). Its GTB-3550 is the first-generation TriKE product candidate which was a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15, all connected by small peptide linkers.

Fairly Valued

The company’s latest PE is -0.16, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 539.33K shares, decreasing 61.40% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 10.50K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 7.52, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.52

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.82

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

GT Biopharma Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 6.85, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.16, which is -93.45% below the recent high of -0.01 and -929.03% above the recent low of -1.60.

Score

Industry at a Glance

Previous score

6.85

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 176/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.00, which is equal to the Biotechnology & Medical Research industry's average of 8.00. The average price target for GT Biopharma Inc is 11.00, with a high of 11.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

11.000

Target Price

+1665.37%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

GT Biopharma Inc

GTBP

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 4.09, which is lower than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 1.13 and the support level at 0.35, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.42

Change

0.67

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.005

Neutral

RSI(14)

41.341

Neutral

STOCH(KDJ)(9,3,3)

17.812

Oversold

ATR(14)

0.054

Low Volatility

CCI(14)

-104.436

Sell

Williams %R

83.684

Oversold

TRIX(12,20)

-0.790

Sell

StochRSI(14)

73.642

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.619

Sell

MA10

0.654

Sell

MA20

0.702

Sell

MA50

0.768

Sell

MA100

1.483

Sell

MA200

1.927

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 15.18%, representing a quarter-over-quarter decrease of 60.27%. The largest institutional shareholder is James Simons, holding a total of 26.30K shares, representing 0.74% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Bristol Capital Advisors, LLC

224.52K

Five Narrow Lane LP

224.40K

Cytovance Biologics Inc

219.46K

Marzilli (Robert A)

200.00K

Armistice Capital LLC

114.48K

+57.89%

BMO Nesbitt Burns Inc.

92.53K

+531.56%

Breen (Michael Martin)

45.21K

+58.40%

Ohri (Manu)

28.33K

+142.86%

Renaissance Technologies LLC

Star Investors

26.30K

Geode Capital Management, L.L.C.

23.84K

+3.25%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 1.27, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.56. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.